---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-277627"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:12:12.916645+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Atea Q3 net loss $42.0M ($0.53/share); HCV Phase 3 C-BEYOND fully enrolled by end-2025; HEV program launched

## Summary
- Net loss of $42.0M ($0.53 diluted EPS) vs $31.2M ($0.37) in Q3 2024; R&D expenses rose to $38.3M.
- Cash, equivalents and marketable securities $329.3M at Sep 30, 2025, down from $454.7M at Dec 31, 2024.
- HCV Phase 3 C-BEYOND (US/Canada) enrollment on track for completion by end 2025; topline mid-2026.
- New HEV development program with two lead candidates AT-587 and AT-2490; IND-enabling studies ongoing.
- Completed $25M stock repurchase program: 7,673,793 shares at avg $3.26; shares outstanding 78,126,796.

## SEC filing metadata
- accession: 0001193125-25-277627
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312525277627/0001193125-25-277627-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312525277627/d47505d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-277627
- JSON: https://secwatch.observer/filing/0001193125-25-277627.json
- Plain text: https://secwatch.observer/filing/0001193125-25-277627.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.